Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shigeyuki Morioka is active.

Publication


Featured researches published by Shigeyuki Morioka.


Biochemical and Biophysical Research Communications | 1986

Different expression of alkaline phosphatase in subclones of human neoplastic salivary duct cell line

Kanemitsu Shirasuna; Shigeyuki Morioka; Kazuya Watatani; Masaru Sugiyama

Human neoplastic salivary cell line (HSGc) and its subclones express alkaline phosphatase (AP) which is sensitive to L-phenylalanine but insensitive to L-homoarginine. Electrophoretic analysis demonstrates two distinct bands of AP, one (sb-1) is heat-stable and another (sb-2) is rather heat-labile and faster mobility than sb-1. The AP activity, especially sb-2, shows high level in less-differentiated clone (HSGc-C5) with increased growth rate but low level in nontumorigenic and well-differentiated clone (HSGc-E1) as compared to parent HSGc. This may suggest that the AP is a possible marker for identification of undifferentiated state in HSGc. This study also indicates that dibutyryl cAMP produces an increase of heat-labile AP in these clones.


Virchows Archiv B Cell Pathology Including Molecular Pathology | 1989

Different contents of glycosaminoglycans in a human neoplastic salivary duct cell line and its subclone with a myoepithelial phenotype.

Kanemitsu Shirasuna; Hideyuki Furusawa; Shigeyuki Morioka; Kazuya Watatani; Tokuzo Matsuya

SummaryThe glycosaminoglycans (GAG) biosynthesized by a neoplastic human salivary duct cell line, HSGc, and by its nontumorigenic subclone, HSGc-E1, having a myoepithelial-like phenotype, were examined by incorporation of [3H]-acetate into GAG. The rate of GAG radiolabeling in HSGc-E1 was significantly greater than that in HSGc. The radiolabeled GAG recovered from HSGc-E1 showed a distribution of 22–32% in the cells and 68–78% secreted into the medium, while the amounts of GAG in the cells and medium of HSGc were equal. Two-dimensional electrophoresis of GAG extracted from the cells demonstrated that HSGc-E1 contained a much greater amount of heparan sulfate (HS, 53.5% of total), while HSGc synthesized hyaluronic acid (HA, 17.5%), HS 38.8%, chondroitin sulfate (Ch-S, 27.6%) and dermatan sulfate (DS, 16.1%). Moreover, treatment of HSGc with sodium butyrate or dibutyryl cyclic AMP (each is a potent inducer of differentiation to myoepithelial-like cells) strongly enhanced GAG synthesis, while dexamethasone (an inducer of differentiation to a more functional duct epithelium) did not stimulate GAG synthesis. These findings suggest that biosynthetic changes in the GAG content of neoplastic salivary cells are associated with their myoepithelial differentiation.


International Journal of Oral and Maxillofacial Surgery | 1987

Serum a-1 -antitrypsin in patients with malignant tumors occurring in the oral region

Kanemitsu Shirasuna; Masaru Sugiyama; Kazuya Watatani; Shigeyuki Morioka; Yasutaka Hayashido

In the present study, we have examined the immunoreactive levels of alpha-1-antitrypsin (AAT) and trypsin-inhibitory capacity (TIC) in the serum of patients with malignant tumors occurring in the oral region. AAT in the MFH group showed significantly high (468 +/- 129 mg/dl, mean +/- SD (n = 4)) as compared to those of other types of sarcoma groups (236 +/- 28 mg/dl, (n = 5)) and healthy controls (226 +/- 36 mg/dl, (n = 75)) (p less than 0.05). Patients with squamous cell carcinoma (SCC) also had increased levels of AAT (269 +/- 35 mg/dl, (n = 18)), but there was no significant difference among other groups including healthy controls. TIC of patients with MFH was higher (2.29 +/- 0.42 IU/ml, (n = 4)) than in the SCC group (1.44 +/- 0.25 IU/ml, (n = 18)), other sarcoma groups 1.21 +/- 0.16 IU/ml, (n = 5)) and controls (1.55 +/- 0.15 IU/ml, (n = 75)). These data suggest that the elevation of AAT and TIC would be helpful in the diagnosis of MFH.


Cancer Research | 1986

Isolation and Characterization of Different Clones Including Myoepithelial-like Variants from a Clonal Neoplastic Epithelial Duct Cell Line of Human Salivary Gland Origin

Kanemitsu Shirasuna; Kazuya Watatani; Masaru Sugiyama; Shigeyuki Morioka; Tadashi Miyazaki


Cancer Research | 1990

Biological Characterization of Pseudocyst-forming Cell Lines from Human Adenoid Cystic Carcinomas of Minor Salivary Gland Origin

Kanemitsu Shirasuna; Kazuya Watatani; Hideyuki Furusawa; Munehisa Saka; Shigeyuki Morioka; Hideo Yoshioka; T. Matsuya


Cancer Research | 1988

Growth Inhibition and Differentiation of Human Salivary Adenocarcinoma Cells by Medium Conditioned with Normal Human Fibroblasts

Kanemitsu Shirasuna; Shigeyuki Morioka; Kazuya Watatani; Yasutaka Hayashido; Hideyuki Furusawa; Masaru Sugiyama; Masaya Okura; Tokuzo Matsuya


Journal of oral surgery | 1991

Clinical evaluation of adjuvant immunotherapy with Sizofiran (SPG) for postoperative head and neck cancer

Isao Fukunaga; Kanemitsu Shirasuna; Hideyuki Furusawa; Tomohiro Taki; Yoshihito Shibano; Masaya Okura; Hideo Yoshioka; Shigeyuki Morioka; Masahiro Urade; Tokuzo Matsuya


Japanese Journal of Oral & Maxillofacial Surgery | 1990

Clinical study on concentration of Cefazolin (CEZ) in maxillary bone tissue

Shigeyuki Morioka; Yasushi Hamamura; Noboru Yakushiji; Katsuya Sakamoto; Hirofumi Miyamoto; Takashi Tsuda; Takafumi Ogura; Kazuhiro Suami; Munehiro Takeda; Isao Fukunaga; Shigeru Minobe; Yasunobu Yasui; Hiroshige Yamauchi; Kanemitsu Shirasuna; Tokuzo Matsuya


Japanese Journal of Oral & Maxillofacial Surgery | 1989

Biological characterization of fibroblasts derived from gingival fibromatosis

Masaya Okura; Kanemitsu Shirasuna; Yasutake Hayashidou; Muneaki Saka; Hideyuki Furusawa; Shigeyuki Morioka; Hideo Yoshioka; T. Matsuya


Journal of oral surgery | 1995

Sialolithiasis of the minor salivary glands of the lip: Report of 3 cases

Seiji Iida; Kanemitsu Shirasuna; Shoichiro Ishii; Shigeyuki Morioka; Yoshiyasu Uchida; Megumi Shikata; Masahiro Nakashima; Tomonao Aikawa; Hidehiko Koizumi; Shigemasa Kubo; Tokuzo Matsuya

Collaboration


Dive into the Shigeyuki Morioka's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge